Form 4: Fortress Biotech CEO Lindsay Rosenwald Acquires 5,000 Shares of Series A Preferred Stock
SEC Form 4 Filing
Fortress Biotech's CEO, Lindsay Rosenwald, recently acquired 5,000 shares of Series A Cumulative Perpetual Preferred Stock at a price of $7.3942 per share.
Summary
- On July 9, 2024, Lindsay Rosenwald, the CEO, President, and Chairman of Fortress Biotech, acquired 5,000 shares of Series A Cumulative Perpetual Preferred Stock.
- The purchase price was $7.3942 per share.
- Following the transaction, Rosenwald directly owns 122,500 shares of the same stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to insider trading. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about a transaction.
Industry Context
This Form 4 filing is a routine disclosure of insider trading activity, which is common for publicly traded companies. It provides transparency into the transactions of company executives and directors.
Stakeholder Impact
- The transaction may have a minor impact on shareholders, as it reflects the CEO's investment in the company's preferred stock.
Key Dates
| Date | Description |
|---|---|
| 07/09/2024 | Date of transaction: Lindsay Rosenwald acquired 5,000 shares of Series A Cumulative Perpetual Preferred Stock. |
| 07/11/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.